Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.
- REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.
- “Our tribody platform is differentiated with its dual engagers including its NK cell engager having a dual mechanism of action, in addition to the conditionally activated T cell engager.
- We are excited about the potential of this platform to produce a pipeline of promising drug candidates that can be effective across numerous solid cancer tumors,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
- Purple Biotech’s cleavable capping technology confines the compound’s therapeutic activity to the local tumor micro environment (TME), which increases the anticipated therapeutic window in patients.